Haven't used Ability Pharmaceuticals yet?
Ask AI

Ask AI about Ability Pharmaceuticals

Generated with AI from 8 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Robert Magee
Reviews 1

Ability Pharmaceuticals has proven to be a reliable company. Their website is user-friendly and provides all the necessary information. The customer support team is attentive and helpful. I am satisfied with their products and services.

Bruce Burton
Reviews 1

I had a pleasant experience with Ability Pharmaceuticals. Their website abilitypharma.com was easy to navigate and provided all the necessary information. The customer support was helpful and responsive. I would highly recommend them to anyone looking for pharmaceutical solutions.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="abilitypharma-com" data-lang="en"></div>
More widgets

About Ability Pharmaceuticals

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.

Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.

Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.